Business Description
Nuvectis Pharma Inc
NAICS : 541714
SIC : 2833
ISIN : US67080T1088
Total Employee Number:
13Description
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.56 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 6 | |||||
3-Year EPS without NRI Growth Rate | 4.4 | |||||
3-Year FCF Growth Rate | 11.8 | |||||
3-Year Book Growth Rate | -9.6 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.28 | |||||
9-Day RSI | 49.23 | |||||
14-Day RSI | 54 | |||||
3-1 Month Momentum % | 25.43 | |||||
6-1 Month Momentum % | 21.87 | |||||
12-1 Month Momentum % | 25.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.27 | |||||
Quick Ratio | 2.27 | |||||
Cash Ratio | 2.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.6 | |||||
Shareholder Yield % | -2.49 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -143.75 | |||||
ROA % | -90.62 | |||||
ROIC % | -496.42 | |||||
3-Year ROIIC % | -184.27 | |||||
ROCE % | -149.6 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 34.33 | |||||
Price-to-Tangible-Book | 34.07 | |||||
EV-to-EBIT | -19.63 | |||||
EV-to-Forward-EBIT | -7.01 | |||||
EV-to-EBITDA | -19.63 | |||||
EV-to-Forward-EBITDA | -19.4 | |||||
EV-to-FCF | -30.25 | |||||
| Price-to-Net-Current-Asset-Value | 34.07 | |||||
| Price-to-Net-Cash | 34.72 | |||||
Earnings Yield (Greenblatt) % | -5.09 | |||||
FCF Yield % | -3.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NVCT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nuvectis Pharma Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.31 | ||
| Beta | -0.8753 | ||
| 3-Year Sharpe Ratio | 0.33 | ||
| 3-Year Sortino Ratio | 0.65 | ||
| Volatility % | 92.89 | ||
| 14-Day RSI | 54 | ||
| 14-Day ATR ($) | 2.062066 | ||
| 20-Day SMA ($) | 18.266 | ||
| 12-1 Month Momentum % | 25.89 | ||
| 52-Week Range ($) | 5.55 - 29.275 | ||
| Shares Outstanding (Mil) | 31.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nuvectis Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nuvectis Pharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-04 | In 115 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 24 days | ||
| General meeting for 2025 | 2026-06-11 10:00 | 10.31 (+5.91%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 8.89 (+4.22%) | ||
| Annual report for 2025 | 2026-02-11 | 8.74 (-3.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-11 | 8.74 (-3.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-04 | 6.36 (-5.22%) | ||
| Second quarter earnings results for 2025 | 2025-08-05 | 7.29 (+7.21%) | ||
| General meeting for 2024 | 2025-06-12 10:00 | 8.83 (-2.97%) | ||
| 3rd Annual H.C. Wainwright BioConnect Investor Conference | 2025-05-20 10:30 | 10.95 (+9.83%) |
Show
Entries
Nuvectis Pharma Inc Frequently Asked Questions
What is Nuvectis Pharma Inc(NVCT)'s stock price today?
The current price of NVCT is $18.40. The 52 week high of NVCT is $29.28 and 52 week low is $5.55.
When is next earnings date of Nuvectis Pharma Inc(NVCT)?
The next earnings date of Nuvectis Pharma Inc(NVCT) is 2026-08-05 Est..
Does Nuvectis Pharma Inc(NVCT) pay dividends? If so, how much?
Nuvectis Pharma Inc(NVCT) does not pay dividend.
Guru Commentaries on NAS:NVCT
No articles.
Press Release
Articles on Nuvectis Pharma Inc
Market Today: Tariff Refund Lifts Nike Earnings; Kroger, FedEx Announce Major Deals; Fourth of July
Jul 01, 2026
Headlines
See More- 1
Jun 30, 2026
At a glance: stocks gapping down premarket
Seeking Alpha • 6:27am
Biggest stock movers Tuesday: ABVX, AVAV, and more
Seeking Alpha • 3:29am
Nuvectis Pharma shares slide 19% on pricing of $100M stock offering
Seeking Alpha • 11:09pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers